{"id":"https://openalex.org/W2730857027","doi":"https://doi.org/10.1080/14397595.2017.1337056","title":"Safety, pharmacokinetics, and efficacy of E6011, an antifractalkine monoclonal antibody, in a first-in-patient phase 1/2 study on rheumatoid arthritis","display_name":"Safety, pharmacokinetics, and efficacy of E6011, an antifractalkine monoclonal antibody, in a first-in-patient phase 1/2 study on rheumatoid arthritis","publication_year":2017,"publication_date":"2017-07-06","ids":{"openalex":"https://openalex.org/W2730857027","doi":"https://doi.org/10.1080/14397595.2017.1337056","mag":"2730857027","pmid":"https://pubmed.ncbi.nlm.nih.gov/28681650"},"language":"en","primary_location":{"id":"doi:10.1080/14397595.2017.1337056","doi":"https://doi.org/10.1080/14397595.2017.1337056","is_oa":false,"landing_page_url":"https://doi.org/10.1080/14397595.2017.1337056","pdf_url":null,"source":{"id":"https://openalex.org/S30446230","display_name":"Modern Rheumatology","issn_l":"1439-7595","issn":["1439-7595","1439-7609"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Modern Rheumatology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5015953107","display_name":"Yoshiya Tanaka","orcid":"https://orcid.org/0000-0002-0807-7139","observed_orcids":["https://orcid.org/0000-0002-0807-7139"]},"institutions":[{"id":"https://openalex.org/I188700360","display_name":"University of Occupational and Environmental Health Japan","ror":"https://ror.org/020p3h829","country_code":"JP","type":"education","lineage":["https://openalex.org/I188700360"]}],"countries":["JP"],"is_corresponding":true,"raw_author_name":"Yoshiya Tanaka","raw_affiliation_strings":["First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan;","institution_ids":["https://openalex.org/I188700360"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083314956","display_name":"Tsutomu Takeuchi","orcid":"https://orcid.org/0000-0003-1111-8218","observed_orcids":["https://orcid.org/0000-0003-1111-8218"]},"institutions":[{"id":"https://openalex.org/I203951103","display_name":"Keio University","ror":"https://ror.org/02kn6nx58","country_code":"JP","type":"education","lineage":["https://openalex.org/I203951103"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Tsutomu Takeuchi","raw_affiliation_strings":["Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan;","institution_ids":["https://openalex.org/I203951103"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014411218","display_name":"Hisanori Umehara","orcid":"https://orcid.org/0000-0001-9833-4647","observed_orcids":["https://orcid.org/0000-0001-9833-4647"]},"institutions":[{"id":"https://openalex.org/I4210148770","display_name":"Nagahama City Hospital","ror":"https://ror.org/05n5d3f06","country_code":"JP","type":"healthcare","lineage":["https://openalex.org/I4210148770"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Hisanori Umehara","raw_affiliation_strings":["Division of Rheumatology and Immunology, Nagahama City Hospital, Shiga, Japan;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Rheumatology and Immunology, Nagahama City Hospital, Shiga, Japan;","institution_ids":["https://openalex.org/I4210148770"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081181665","display_name":"Toshihiro Nanki","orcid":"https://orcid.org/0000-0002-3482-074X","observed_orcids":["https://orcid.org/0000-0002-3482-074X"]},"institutions":[{"id":"https://openalex.org/I129634264","display_name":"Toho University","ror":"https://ror.org/02hcx7n63","country_code":"JP","type":"education","lineage":["https://openalex.org/I129634264"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Toshihiro Nanki","raw_affiliation_strings":["Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Tokyo, Japan;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Tokyo, Japan;","institution_ids":["https://openalex.org/I129634264"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061087608","display_name":"Nobuyuki Yasuda","orcid":"https://orcid.org/0000-0003-0117-0784","observed_orcids":["https://orcid.org/0000-0003-0117-0784"]},"institutions":[{"id":"https://openalex.org/I4210115373","display_name":"KAN Research Institute","ror":"https://ror.org/02b3jn477","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210115373"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Nobuyuki Yasuda","raw_affiliation_strings":["KAN Research Institute, Inc., Kobe, Japan;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"KAN Research Institute, Inc., Kobe, Japan;","institution_ids":["https://openalex.org/I4210115373"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051805339","display_name":"Fumitoshi Tago","orcid":"https://orcid.org/0000-0002-2283-8846","observed_orcids":["https://orcid.org/0000-0002-2283-8846","https://orcid.org/0000-0002-1235-2244"]},"institutions":[{"id":"https://openalex.org/I55881946","display_name":"Eisai (Japan)","ror":"https://ror.org/04vvh7p27","country_code":"JP","type":"company","lineage":["https://openalex.org/I55881946"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Fumitoshi Tago","raw_affiliation_strings":["Eisai Co., Ltd., Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eisai Co., Ltd., Tokyo, Japan","institution_ids":["https://openalex.org/I55881946"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085663380","display_name":"Makoto Kawakubo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I55881946","display_name":"Eisai (Japan)","ror":"https://ror.org/04vvh7p27","country_code":"JP","type":"company","lineage":["https://openalex.org/I55881946"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Makoto Kawakubo","raw_affiliation_strings":["Eisai Co., Ltd., Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eisai Co., Ltd., Tokyo, Japan","institution_ids":["https://openalex.org/I55881946"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006456433","display_name":"Yasumi Kitahara","orcid":"https://orcid.org/0000-0003-4880-0325","observed_orcids":["https://orcid.org/0000-0003-4880-0325"]},"institutions":[{"id":"https://openalex.org/I55881946","display_name":"Eisai (Japan)","ror":"https://ror.org/04vvh7p27","country_code":"JP","type":"company","lineage":["https://openalex.org/I55881946"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Yasumi Kitahara","raw_affiliation_strings":["Eisai Co., Ltd., Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eisai Co., Ltd., Tokyo, Japan","institution_ids":["https://openalex.org/I55881946"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001074370","display_name":"Seiichiro Hojo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I55881946","display_name":"Eisai (Japan)","ror":"https://ror.org/04vvh7p27","country_code":"JP","type":"company","lineage":["https://openalex.org/I55881946"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Seiichiro Hojo","raw_affiliation_strings":["Eisai Co., Ltd., Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eisai Co., Ltd., Tokyo, Japan","institution_ids":["https://openalex.org/I55881946"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057330515","display_name":"Tetsu Kawano","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210115373","display_name":"KAN Research Institute","ror":"https://ror.org/02b3jn477","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210115373"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Tetsu Kawano","raw_affiliation_strings":["KAN Research Institute, Inc., Kobe, Japan;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"KAN Research Institute, Inc., Kobe, Japan;","institution_ids":["https://openalex.org/I4210115373"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5027763231","display_name":"Toshio Imai","orcid":"https://orcid.org/0000-0002-4022-1962","observed_orcids":["https://orcid.org/0000-0002-4022-1962"]},"institutions":[{"id":"https://openalex.org/I4210115373","display_name":"KAN Research Institute","ror":"https://ror.org/02b3jn477","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210115373"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Toshio Imai","raw_affiliation_strings":["KAN Research Institute, Inc., Kobe, Japan;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"KAN Research Institute, Inc., Kobe, Japan;","institution_ids":["https://openalex.org/I4210115373"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":6,"corresponding_author_ids":["https://openalex.org/A5015953107"],"corresponding_institution_ids":["https://openalex.org/I188700360"],"apc_list":{"value":3208,"currency":"USD","value_usd":3208},"apc_paid":null,"fwci":7.4614,"has_fulltext":false,"cited_by_count":61,"citation_normalized_percentile":{"value":0.98187936,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":89,"max":100},"biblio":{"volume":"28","issue":"1","first_page":"58","last_page":"65"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10200","display_name":"Rheumatoid Arthritis Research and Therapies","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10200","display_name":"Rheumatoid Arthritis Research and Therapies","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T13026","display_name":"Natural Compounds in Disease Treatment","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2707","display_name":"Complementary and alternative medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cx3cl1","display_name":"fractalkine","score":0.9769999980926514},{"id":"https://openalex.org/keywords/cx3cr1","display_name":"CX3CR1","score":0.8939999938011169},{"id":"https://openalex.org/keywords/rheumatoid-arthritis","display_name":"rheumatoid arthritis","score":0.9959999918937683},{"id":"https://openalex.org/keywords/humanized-antibody","display_name":"humanized monoclonal antibody","score":0.7590000033378601},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8510000109672546},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.8769999742507935},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.7319999933242798},{"id":"https://openalex.org/keywords/acr-response","display_name":"ACR response","score":0.6140000224113464},{"id":"https://openalex.org/keywords/methotrexate-refractory-rheumatoid-arthritis","display_name":"methotrexate-refractory rheumatoid arthritis","score":0.7540000081062317}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9544605016708374},{"id":"https://openalex.org/C2777575956","wikidata":"https://www.wikidata.org/wiki/Q187255","display_name":"Rheumatoid arthritis","level":2,"score":0.8393124341964722},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6867417097091675},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.6422722935676575},{"id":"https://openalex.org/C198451711","wikidata":"https://www.wikidata.org/wiki/Q327657","display_name":"Rheumatology","level":2,"score":0.597216784954071},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5421034693717957},{"id":"https://openalex.org/C2781059491","wikidata":"https://www.wikidata.org/wiki/Q422232","display_name":"Methotrexate","level":2,"score":0.5137063264846802},{"id":"https://openalex.org/C61511704","wikidata":"https://www.wikidata.org/wiki/Q1671857","display_name":"Incidence (geometry)","level":2,"score":0.4667406976222992},{"id":"https://openalex.org/C2777077863","wikidata":"https://www.wikidata.org/wiki/Q170990","display_name":"Arthritis","level":2,"score":0.4631599187850952},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.44286543130874634},{"id":"https://openalex.org/C2777138892","wikidata":"https://www.wikidata.org/wiki/Q415264","display_name":"Infliximab","level":3,"score":0.4221656322479248},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.37899157404899597},{"id":"https://openalex.org/C17991360","wikidata":"https://www.wikidata.org/wiki/Q21173843","display_name":"Tumor necrosis factor alpha","level":2,"score":0.30923861265182495},{"id":"https://openalex.org/C120665830","wikidata":"https://www.wikidata.org/wiki/Q14620","display_name":"Optics","level":1,"score":0.0},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.0}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D001172","descriptor_name":"Arthritis, Rheumatoid","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018501","descriptor_name":"Antirheumatic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D018501","descriptor_name":"Antirheumatic Agents","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D018501","descriptor_name":"Antirheumatic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D018501","descriptor_name":"Antirheumatic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D054428","descriptor_name":"Chemokine CX3CL1","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":true},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1080/14397595.2017.1337056","doi":"https://doi.org/10.1080/14397595.2017.1337056","is_oa":false,"landing_page_url":"https://doi.org/10.1080/14397595.2017.1337056","pdf_url":null,"source":{"id":"https://openalex.org/S30446230","display_name":"Modern Rheumatology","issn_l":"1439-7595","issn":["1439-7595","1439-7609"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Modern Rheumatology","raw_type":"journal-article"},{"id":"pmid:28681650","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/28681650","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Modern rheumatology","raw_type":"Clinical Trial, Phase I"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9940000176429749,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320307778","display_name":"Novartis","ror":"https://ror.org/02f9zrr09"},{"id":"https://openalex.org/F4320309117","display_name":"AbbVie","ror":"https://ror.org/02g5p4n58"},{"id":"https://openalex.org/F4320310465","display_name":"Takeda Pharmaceutical Company","ror":"https://ror.org/04hjbmv12"},{"id":"https://openalex.org/F4320315887","display_name":"GlaxoSmithKline Japan","ror":"https://ror.org/01j6sxy67"},{"id":"https://openalex.org/F4320321625","display_name":"Daiichi-Sankyo","ror":"https://ror.org/027y26122"},{"id":"https://openalex.org/F4320322148","display_name":"Eisai","ror":"https://ror.org/04vvh7p27"},{"id":"https://openalex.org/F4320323024","display_name":"Astellas Pharma","ror":"https://ror.org/01cjash87"},{"id":"https://openalex.org/F4320323880","display_name":"Taisho Toyama Pharmaceutical Company","ror":"https://ror.org/033nw2736"},{"id":"https://openalex.org/F4320324271","display_name":"Astellas Foundation for Research on Metabolic Disorders","ror":"https://ror.org/01cjash87"},{"id":"https://openalex.org/F4320327566","display_name":"Mitsubishi Tanabe Pharma Corporation","ror":"https://ror.org/038ehsm73"},{"id":"https://openalex.org/F4320333003","display_name":"Chugai Pharmaceutical","ror":"https://ror.org/01vepzj85"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":27,"referenced_works":["https://openalex.org/W40915523","https://openalex.org/W1519962349","https://openalex.org/W1560566673","https://openalex.org/W1967974124","https://openalex.org/W1969945556","https://openalex.org/W1989108502","https://openalex.org/W2000905503","https://openalex.org/W2006566716","https://openalex.org/W2008669330","https://openalex.org/W2053315646","https://openalex.org/W2065419533","https://openalex.org/W2074838002","https://openalex.org/W2075824749","https://openalex.org/W2100974168","https://openalex.org/W2110177517","https://openalex.org/W2128514908","https://openalex.org/W2128952811","https://openalex.org/W2143972196","https://openalex.org/W2145738273","https://openalex.org/W2147303583","https://openalex.org/W2148357532","https://openalex.org/W2152348310","https://openalex.org/W2159106700","https://openalex.org/W2159520783","https://openalex.org/W2165956033","https://openalex.org/W2166328404","https://openalex.org/W2493812037"],"related_works":["https://openalex.org/W2554124068","https://openalex.org/W2756348063","https://openalex.org/W2946943217","https://openalex.org/W2951738485","https://openalex.org/W3092648011","https://openalex.org/W3118878418","https://openalex.org/W3105932569","https://openalex.org/W4317651631","https://openalex.org/W4317651441","https://openalex.org/W4237105058"],"abstract_inverted_index":{"OBJECTIVE:":[0],"Fractalkine":[1],"(CX3CL1/FKN)":[2],"is":[3],"a":[4,32],"chemokine":[5,13],"that":[6,187],"regulates":[7],"chemotaxis":[8],"and":[9,71,82,91,104,133,142,151,158,161,175],"adhesion":[10],"of":[11,30,115,128],"CX3C":[12],"receptor":[14],"1":[15],"(CX3CR1)-expressing":[16],"inflammatory":[17],"cells.":[18],"We":[19],"conducted":[20],"the":[21,88,111,118,145,154,164],"first":[22],"phase":[23],"1/2,":[24],"open-label,":[25],"multiple":[26],"ascending":[27],"dose":[28,124],"study":[29],"E6011,":[31],"humanized":[33],"anti-FKN":[34],"monoclonal":[35],"antibody,":[36],"in":[37,87,110,144,153,163,178,194],"Japanese":[38],"rheumatoid":[39],"arthritis":[40],"(RA)":[41],"patients":[42,49,180],"(clinicaltrial.gov":[43],"identifier:":[44],"NCT02196558).":[45],"METHODS:":[46],"Active":[47],"RA":[48,179,196],"with":[50],"an":[51,190],"inadequate":[52],"response":[53,193],"or":[54,58,101,113],"intolerance":[55],"to":[56,172],"methotrexate":[57],"tumor":[59],"necrosis":[60],"factor":[61],"(TNF)":[62],"inhibitor":[63],"received":[64],"E6011":[65,121,170,188],"at":[66,136],"week":[67,137],"0,":[68],"1,":[69],"2,":[70],"thereafter":[72],"every":[73],"2":[74],"weeks":[75],"for":[76],"12":[77,138],"weeks.":[78],"RESULTS:":[79],"Twelve,":[80],"15,":[81],"10":[83],"subjects":[84],"were":[85,108,139],"enrolled":[86],"100,":[89],"200,":[90],"400":[92,165],"mg":[93,147,156,166],"cohorts,":[94],"respectively.":[95,168],"No":[96],"severe":[97],"adverse":[98],"events":[99],"(AEs)":[100],"deaths":[102],"occurred,":[103],"no":[105],"major":[106],"differences":[107],"observed":[109],"incidence":[112],"severity":[114],"AEs":[116],"across":[117],"cohorts.":[119],"Serum":[120],"concentrations":[122],"increased":[123],"dependently.":[125],"American":[126],"College":[127],"Rheumatology":[129],"(ACR)":[130],"20,":[131],"50,":[132],"70":[134],"responses":[135],"75.0%,":[140],"33.3%,":[141],"8.3%":[143],"100":[146],"cohort;":[148,157],"66.7%,":[149],"20.0%,":[150],"13.3%":[152],"200":[155],"60.0%,":[159],"30.0%,":[160],"20.0%":[162],"cohort,":[167],"CONCLUSIONS:":[169],"appeared":[171],"be":[173],"safe":[174],"well":[176],"tolerated":[177],"during":[181],"this":[182],"12-week":[183],"treatment":[184],"period,":[185],"suggesting":[186],"has":[189],"effective":[191],"clinical":[192],"active":[195],"patients.":[197]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":4},{"year":2021,"cited_by_count":13},{"year":2020,"cited_by_count":14},{"year":2019,"cited_by_count":17},{"year":2018,"cited_by_count":4},{"year":2017,"cited_by_count":1}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2017-07-14T00:00:00"}